Cellectar Biosciences, Inc. (CLRB)
NASDAQ: CLRB · Real-Time Price · USD
2.200
-0.150 (-6.38%)
Sep 22, 2026, 4:00 PM EDT - Market closed
Cellectar Biosciences Balance Sheet
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
Assets
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Cash & Equivalents | 33.99 | 13.2 | 23.29 | 9.56 | 19.87 | 35.7 |
Cash & Short-Term Investments | 33.99 | 13.2 | 23.29 | 9.56 | 19.87 | 35.7 |
Cash Growth | 207.89% | -43.34% | 143.48% | -51.85% | -44.36% | -37.54% |
Prepaid Expenses | 0.88 | 0.84 | 0.96 | 0.89 | 0.66 | 0.87 |
Total Current Assets | 34.88 | 14.04 | 24.25 | 10.45 | 20.53 | 36.57 |
Property, Plant & Equipment | 1.74 | 0.91 | 1.19 | 1.59 | 0.98 | 0.55 |
Other Long-Term Assets | 0.02 | 0.03 | 0.03 | 0.03 | 0.08 | 0.08 |
Total Assets | 36.64 | 14.98 | 25.47 | 12.08 | 21.59 | 37.2 |
Liabilities
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Accounts Payable | 5.22 | 1.44 | 4.11 | 9.18 | 2.56 | 1.41 |
Accrued Expenses | - | 2.48 | 2.17 | - | 2.91 | 2.44 |
Current Portion of Leases | 0 | 0.1 | 0.08 | 0.06 | 0.05 | 0.14 |
Other Current Liabilities | 0.02 | 0.73 | 3.03 | 16.12 | 5.98 | - |
Total Current Liabilities | 5.24 | 4.75 | 9.39 | 25.36 | 11.5 | 3.99 |
Long-Term Leases | 1.53 | 0.31 | 0.41 | 0.49 | 0.55 | 0.17 |
Total Liabilities | 6.77 | 5.06 | 9.8 | 25.85 | 12.05 | 4.16 |
Shareholders' Equity
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Common Stock | 0 | 0 | 0 | 0 | 0 | 0 |
Additional Paid-In Capital | 311.59 | 277.15 | 261.12 | 182.92 | 168.14 | 182.56 |
Retained Earnings | -281.72 | -269.13 | -247.34 | -202.76 | -159.99 | -150.9 |
Total Common Equity | 29.87 | 8.02 | 13.77 | -19.84 | 8.15 | 31.66 |
Shareholders' Equity | 29.87 | 9.92 | 15.68 | -13.78 | 9.54 | 33.05 |
Total Liabilities & Equity | 36.64 | 14.98 | 25.47 | 12.08 | 21.59 | 37.2 |
Additional Metrics
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Total Debt | 1.53 | 0.41 | 0.49 | 0.55 | 0.6 | 0.3 |
Net Cash (Debt) | 32.46 | 12.79 | 22.79 | 9.01 | 19.26 | 35.4 |
Net Cash Growth | 206.61% | -43.91% | 152.94% | -53.22% | -45.59% | -37.61% |
Net Cash Per Share | 5.45 | 4.90 | 18.41 | 22.12 | 81.90 | 191.31 |
Filing Date Shares Outstanding | 9.45 | 4.24 | 1.54 | 1.08 | 0.32 | 0.2 |
Total Common Shares Outstanding | 8.25 | 4.24 | 1.54 | 0.69 | 0.31 | 0.2 |
Working Capital | 29.64 | 9.29 | 14.86 | -14.91 | 9.03 | 32.58 |
Book Value Per Share | 3.62 | 1.89 | 8.97 | -28.69 | 26.06 | 155.46 |
Tangible Book Value | 29.87 | 8.02 | 13.77 | -19.84 | 8.15 | 31.66 |
Tangible Book Value Per Share | 3.62 | 1.89 | 8.97 | -28.69 | 26.06 | 155.46 |
Machinery | - | - | - | - | 0.8 | 0.58 |
Leasehold Improvements | - | - | - | - | 0.31 | 0.31 |